Horseshoe Crab Peptide Tachyplesin Kills Leishmania Parasites Causing Visceral Leishmaniasis
Tachyplesin, an antimicrobial peptide from horseshoe crab, emerged as an effective anti-leishmanial agent against the intracellular parasite Leishmania donovani, offering a potential alternative to drug-resistant conventional treatments.
Quick Facts
What This Study Found
Tachyplesin demonstrated effective anti-leishmanial activity against Leishmania donovani, the causative agent of visceral leishmaniasis, through a peptide-mediated parasite killing mechanism.
Key Numbers
Tachyplesin: membrane disruption mechanism; cysteine-dependent activity; dual antimicrobial + cargo delivery function
How They Did This
In vitro and/or in vivo study testing tachyplesin antimicrobial peptide against Leishmania donovani. Anti-parasitic activity assessment.
Why This Research Matters
Visceral leishmaniasis kills tens of thousands annually and drug resistance is growing. AMPs like tachyplesin offer fundamentally different killing mechanisms that could overcome resistance to current antimonial and amphotericin B treatments.
The Bigger Picture
Marine-derived antimicrobial peptides are a growing source of anti-parasitic leads. Tachyplesin adds to the evidence that AMPs can target not just bacteria but also the protozoan parasites causing neglected tropical diseases.
What This Study Doesn't Tell Us
Preclinical data. Tachyplesin delivery to intracellular parasites (inside macrophages) is challenging. Toxicity to host cells needs assessment. Manufacturing and cost concerns for tropical disease applications.
Questions This Raises
- ?Can tachyplesin reach parasites hiding inside macrophages?
- ?What is tachyplesin's selectivity index for Leishmania versus human cells?
- ?Could tachyplesin be combined with existing anti-leishmanial drugs?
Trust & Context
- Key Stat:
- AMP vs parasite Tachyplesin — originally studied for antibacterial activity — proves effective against Leishmania parasites, expanding antimicrobial peptide applications to neglected tropical diseases
- Evidence Grade:
- Low evidence grade: preclinical anti-parasitic testing. Important for neglected disease drug development.
- Study Age:
- Published 2021.
- Original Title:
- Peptide-mediated leishmaniasis management strategy: Tachyplesin emerges as an effective anti-leishmanial peptide against Leishmania donovani.
- Published In:
- Biochimica et biophysica acta. Biomembranes, 1863(8), 183629 (2021)
- Authors:
- Kumar, Vivek(2), Chugh, Archana(3)
- Database ID:
- RPEP-05516
Evidence Hierarchy
Frequently Asked Questions
What is tachyplesin?
Tachyplesin is an antimicrobial peptide found in the blood cells of horseshoe crabs, where it helps these ancient animals fight infections. It kills pathogens by disrupting their cell membranes — a mechanism now being explored against parasites.
Why is visceral leishmaniasis hard to treat?
The Leishmania parasite hides inside the body's own immune cells (macrophages), making it difficult for drugs to reach. Current treatments like antimonials are toxic and increasingly ineffective due to resistance. New approaches like antimicrobial peptides offer hope.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05516APA
Kumar, Vivek; Chugh, Archana. (2021). Peptide-mediated leishmaniasis management strategy: Tachyplesin emerges as an effective anti-leishmanial peptide against Leishmania donovani.. Biochimica et biophysica acta. Biomembranes, 1863(8), 183629. https://doi.org/10.1016/j.bbamem.2021.183629
MLA
Kumar, Vivek, et al. "Peptide-mediated leishmaniasis management strategy: Tachyplesin emerges as an effective anti-leishmanial peptide against Leishmania donovani.." Biochimica et biophysica acta. Biomembranes, 2021. https://doi.org/10.1016/j.bbamem.2021.183629
RethinkPeptides
RethinkPeptides Research Database. "Peptide-mediated leishmaniasis management strategy: Tachyple..." RPEP-05516. Retrieved from https://rethinkpeptides.com/research/kumar-2021-peptidemediated-leishmaniasis-management-strategy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.